Ciphergen Taps Mosaic to Develop Reimbursement Plan for Ovarian Cancer Dx

Dec 22, 2006

NEW YORK (GenomeWeb News) - Mosaic Health Care Consultants has agreed to develop reimbursement strategies and programs for Ciphergen Biosystems' ovarian cancer test, Ciphergen said yesterday.

Ciphergen's ovarian cancer triage test, which the company plans to submit for FDA approval after it completes clinical trials, uses a biomarker panel to measure risk stratification.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Mouse Fight

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Seeing the Interactions

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

This Week in Science

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

For Millions

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.

Featured White Papers

Lipid Removal With Reference Applications in Serum and Bile Proteomics

Albumin & IgG Removal Reference Applications

95-plex Immune Cell Phenotyping Assay

Oct

10

Featured Webinar

GenomeWeb/ABRF 2017 Webinar Series: Ask the Experts: Ensuring High-Quality Proteomic Studies with Core Lab Resources

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.

Main menu